Immune therapy: a new therapy for acute myeloid leukemia
Although complete remission could be achieved in about 60%–70% of acute myeloid leukemia (AML) patients after conventional chemotherapy, relapse and the state of being refractory to treatment remain the main cause of death. In addition, there is a great need for less intensive regimens for all medic...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Health
2023-03-01
|
| Series: | Blood Science |
| Online Access: | http://journals.lww.com/10.1097/BS9.0000000000000140 |
| _version_ | 1797671797842247680 |
|---|---|
| author | Chen Tian Zehui Chen |
| author_facet | Chen Tian Zehui Chen |
| author_sort | Chen Tian |
| collection | DOAJ |
| description | Although complete remission could be achieved in about 60%–70% of acute myeloid leukemia (AML) patients after conventional chemotherapy, relapse and the state of being refractory to treatment remain the main cause of death. In addition, there is a great need for less intensive regimens for all medically frail patients (both due to age/comorbidity and treatment-related). Immune therapy anticipates improved prognosis and reduced toxicities, which may offer novel therapeutic rationales. However, one of the major difficulties in developing immune therapies against AML is that the target antigens are also significantly expressed on healthy hematopoietic stem cells; B-cell malignancies are different because CD20/CD19/healthy B-cells are readily replaceable. Only the anti-CD33 antibody-drug conjugate gemtuzumab-ozogamicin is approved by the FDA for AML. Thus, drug development remains extremely active, although it is still in its infancy. This review summarizes the clinical results of immune therapeutic agents for AML, such as antibody-based drugs, chimeric antigen receptor therapy, checkpoint inhibitors, and vaccines. |
| first_indexed | 2024-03-11T21:20:43Z |
| format | Article |
| id | doaj.art-374c9821f5c5494e80f4ada853d4837c |
| institution | Directory Open Access Journal |
| issn | 2543-6368 |
| language | English |
| last_indexed | 2024-03-11T21:20:43Z |
| publishDate | 2023-03-01 |
| publisher | Wolters Kluwer Health |
| record_format | Article |
| series | Blood Science |
| spelling | doaj.art-374c9821f5c5494e80f4ada853d4837c2023-09-28T07:06:17ZengWolters Kluwer HealthBlood Science2543-63682023-03-0151152410.1097/BS9.0000000000000140202303000-00002Immune therapy: a new therapy for acute myeloid leukemiaChen Tian0Zehui Chen1a Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, Chinaa Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, ChinaAlthough complete remission could be achieved in about 60%–70% of acute myeloid leukemia (AML) patients after conventional chemotherapy, relapse and the state of being refractory to treatment remain the main cause of death. In addition, there is a great need for less intensive regimens for all medically frail patients (both due to age/comorbidity and treatment-related). Immune therapy anticipates improved prognosis and reduced toxicities, which may offer novel therapeutic rationales. However, one of the major difficulties in developing immune therapies against AML is that the target antigens are also significantly expressed on healthy hematopoietic stem cells; B-cell malignancies are different because CD20/CD19/healthy B-cells are readily replaceable. Only the anti-CD33 antibody-drug conjugate gemtuzumab-ozogamicin is approved by the FDA for AML. Thus, drug development remains extremely active, although it is still in its infancy. This review summarizes the clinical results of immune therapeutic agents for AML, such as antibody-based drugs, chimeric antigen receptor therapy, checkpoint inhibitors, and vaccines.http://journals.lww.com/10.1097/BS9.0000000000000140 |
| spellingShingle | Chen Tian Zehui Chen Immune therapy: a new therapy for acute myeloid leukemia Blood Science |
| title | Immune therapy: a new therapy for acute myeloid leukemia |
| title_full | Immune therapy: a new therapy for acute myeloid leukemia |
| title_fullStr | Immune therapy: a new therapy for acute myeloid leukemia |
| title_full_unstemmed | Immune therapy: a new therapy for acute myeloid leukemia |
| title_short | Immune therapy: a new therapy for acute myeloid leukemia |
| title_sort | immune therapy a new therapy for acute myeloid leukemia |
| url | http://journals.lww.com/10.1097/BS9.0000000000000140 |
| work_keys_str_mv | AT chentian immunetherapyanewtherapyforacutemyeloidleukemia AT zehuichen immunetherapyanewtherapyforacutemyeloidleukemia |